Lyndsey Elizabeth Crennen Sells 442 Shares of Mesa Laboratories (NASDAQ:MLAB) Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen sold 442 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $89.50, for a total transaction of $39,559.00. Following the transaction, the chief accounting officer owned 2,020 shares in the company, valued at $180,790. This represents a 17.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lyndsey Elizabeth Crennen also recently made the following trade(s):

• On Tuesday, June 16th, Lyndsey Elizabeth Crennen sold 118 shares of Mesa Laboratories stock. The shares were sold at an average price of $101.27, for a total value of $11,949.86.

Mesa Laboratories Stock Performance

Shares of MLAB opened at $94.45 on Thursday. Mesa Laboratories, Inc. has a one year low of $55.45 and a one year high of $113.99. The company has a market cap of $521.36 million, a PE ratio of 78.71 and a beta of 0.94. The stock has a 50-day moving average of $101.80 and a 200-day moving average of $91.21. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.78 by ($0.25). The firm had revenue of $63.72 million for the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same period last year, the company posted ($1.31) earnings per share.

Mesa Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Friday, May 29th were given a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, May 29th. Mesa Laboratories’s dividend payout ratio is presently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in Mesa Laboratories by 5.9% during the 1st quarter. Bank of America Corp DE now owns 57,871 shares of the medical instruments supplier’s stock valued at $5,117,000 after purchasing an additional 3,207 shares during the last quarter. Royal Bank of Canada increased its holdings in Mesa Laboratories by 143.3% during the 1st quarter. Royal Bank of Canada now owns 13,275 shares of the medical instruments supplier’s stock worth $1,173,000 after purchasing an additional 7,818 shares in the last quarter. Quantinno Capital Management LP raised its stake in shares of Mesa Laboratories by 17.9% in the first quarter. Quantinno Capital Management LP now owns 4,318 shares of the medical instruments supplier’s stock worth $382,000 after purchasing an additional 657 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Mesa Laboratories in the first quarter worth approximately $1,797,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Mesa Laboratories by 802.9% in the first quarter. Renaissance Technologies LLC now owns 31,600 shares of the medical instruments supplier’s stock valued at $2,794,000 after purchasing an additional 28,100 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Mesa Laboratories presently has an average rating of “Reduce” and an average target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.